Morbidity and mortality reduction associated with polysomnography testing in idiopathic pulmonary fibrosis: a population-based cohort study

Table 1 Cohort baseline characteristics, before and after propensity score matching (abridged version^*)

Baseline characteristics	Prior to propensity score matching			After propensity score matching
Baseline characteristics	Exposed N = 201	Controls N = 4843	Standardized difference^†	Exposed N = 189	Controls N = 189	Standardized difference^†
Age (mean + SD)	75.9 ± 6.2	78.3 ± 6.8	0.37	76.2 ± 6.1	76.4 ± 6.8	0.04
Women (%)	33.8	45.1	0.23	33.3	33.3	0.00
Respiratory-related hospitalization past year (%)	19.9	9.1	0.31	18.5	18.5	0.00
ICU admission during respiratory-related hospitalization past year (%)	4.0	1.5	0.15	4.2	4.8	0.03
Congestive heart failure (%)	46.3	29.8	0.34	45.5	45.5	0.00
Systemic corticosteroid receipt past year (%)	37.3	33.0	0.09	37.0	37.0	0.00
Respiratory antibiotic receipt past year (%)	72.1	66.5	0.12	72.0	73.5	0.04
Anti-fibrotic drug^§ receipt past year (%)	^‡	0.9	0.09	^‡	^‡	0.00
Total number outpatient visits past year (mean + SD)	19.2 ± 10.2	15.7 ± 9.2	0.36	18.9 ± 10.0	18.1 ± 9.3	0.09
CT Chest scan past year (%)	67.7	54.7	0.27	66.7	69.3	0.06
Echocardiogram past year (%)	65.7	43.8	0.45	64.0	64.6	0.01
Exercise oximetry past year (%)	38.3	31.8	0.14	37.6	37.6	0.00
Pulmonary embolism^ǁ (%)	6.0	3.2	0.13	6.3	6.9	0.02
COPD (%)	70.6	67.6	0.07	69.8	68.8	0.02
GERD^ǁ (%)	6.5	5.2	0.06	6.3	5.8	0.02
Myocardial infarction (%)	14.9	10.0	0.15	14.3	16.4	0.06
Other pulmonary disease^ǁ^¶ (%)	94.5	87.4	0.25	94.2	94.7	0.02
Opioid receipt past 3 months (%)	17.9	17.8	0.00	19.0	19.0	0.00
Diuretic medication receipt past 3 months (%)	36.8	23.8	0.29	34.4	37.0	0.06
Other cardiac drug^** receipt past 3 months (%)	77.6	67.3	0.23	77.2	77.8	0.01

COPD = chronic obstructive pulmonary disease; GERD = gastroesophageal reflux; ICU = intensive care unit; ODB = Ontario Drug Benefit; SD = standard deviation
^*A full list of the variables included in the propensity score model can be found in the Additional file 1
^†Standardized differences of > 0.10 are thought to indicate potentially meaningful differences
^‡Data has been suppressed, according to ICES guidelines, because of small sample size
^§Includes Pirfenidone and Nintedanib
^ǁPresence of comorbidities was based on 3-year look-back from the index date
^¶Includes asthma, bronchiectasis, occupational lung disease, pleural effusion, interstitial disease, pneumothorax, atelectasis and other
^**Includes beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARB)

ISSN: 1471-2466